Search

Basilea's derazantinib - a differentiated FGFR inhibitor

We published a research note today exploring the potential for Basilea's lead oncology candidate derazantinib.



Basilea's anti-infectives franchise is relatively well understood, however, we believe that the emerging oncology franchise has been overlooked. Derazantinib is an FGFR inhibitor with broad applicability in treating a variety of cancers. The FGFR inhibitor space is competitive, and others are ahead of Basilea, but the market potential for effective FGFR-targeting therapies is large. It involves many difficult to treat cancers, and competitors have already validated the approach.


Derazantinib still has a significant opportunity in monotherapy but we believe its potential to boost the activity of immunotherapy has been missed. Derazantinib's activity against the CSF-1/CSF1R pathway appears to differentiate it from competitors. The CSF-1/CSF1R pathway is responsible for effectively blunting the effectiveness of the checkpoint inhibitors (CKIs). Consequently, if derazantinib is successful in combination with CKIs, it could be a leader rather than a fast-follower. Basilea has two trials ongoing to test this theory in combination with Roche's Tecentriq.


We have calculated a discounted cash flow fair value of CHF 120 for Basilea. See the full research note here.


IMPORTANT:

Basilea Pharmaceutica is a client of Calvine Partners and as such, this publication is not independent and should be considered a marketing communication under FCA Rules. None of the information contained in this publication should be considered as any form of advice.

Link to full disclosures.



159 views0 comments

Calvine Partners LLP, Registered in Scotland, Partnership No. SO306987

Registered address: 23 Melville Street, Edinburgh, EH3 7PE

Privacy Policy

Linkedin%20icon_edited.png